LISCure Biosciences announces the signing of a proprietary technology license agreement and stock purchase agreement with Mayo Clinic – QNT Press Release


Seoul, Korea, August 1, 2021 /PRNewswire/ – LISCure Biosciences, Inc. (“LISCure”) has signed a proprietary technology licensing and development cooperation agreement and a stock purchase agreement with Mayo Clinic to promote LISCure in non-alcoholic steatohepatitis (NASH) Microbiome therapy.

The two entities previously signed a research cooperation agreement for NASH candidates in the first half of 2021.

According to the agreement, the company will acquire Mayo Clinic’s proprietary technology to establish a NASH new drug development program. As part of the agreement, Mayo Clinic will become a shareholder of LISCure, the first Korean biotech company to acquire equity…

The full story on Benzinga.com



Source link

Recommended For You

About the Author: News Center